Objective: To use the Continuous Glucose Monitoring System (CGMS, MiniMed, Sylmar, Calif) to determine if bedtime blood glucose levels were associated with the occurrence of nocturnal hypoglycemia.
the Diabetes Control and Complications Trial, 53% of episodes of severe hypoglycemia occurred at night. [3] [4] [5] There are numerous reports indicating a high incidence of nocturnal hypoglycemia in the pediatric population. [6] [7] [8] [9] [10] On any given night, the incidence has been reported to be between 14% to 47%, with up to half of the episodes undetected by the subject. [6] [7] [8] This, in part, may be due to the fact that young children have innate hypoglycemia unawareness that is exacerbated by repeated episodes of hypoglycemia.
In 1985, Pramming et al 11 attempted to correlate the bedtime blood glucose concentration with the risk of nocturnal hypoglycemia. They found that in patients who went to bed with glucose levels of ≤108 mg/dL, there was an 80% chance for hypoglycemia. In a study involving 135 pediatric patients, a bedtime blood glucose concentration of ≤100 mg/dL had a positive predictive value of 24% for subsequent hypoglycemia and a negative predictive value of 90%. 9 As a result, Santiago 1 articulated that health care providers must encourage children and youth with diabetes to measure blood glucose levels before bedtime. He further suggested that they must train families to supplement the bedtime snack when bedtime glucose measurements are below a certain level. For most pediatric
The occurrence of hypoglycemia at night is particularly worrisome to children and adolescents with type 1 diabetes. 1 Recently, our center began to use the MiniMed Continuous Glucose Monitoring System (CGMS, MiniMed, Sylmar, Calif). 12 CGMS measures interstitial glucose levels every 5 minutes with a sensor placed in the subcutaneous tissue that can be easily tolerated by pediatric patients and that has proven accuracy. We attempted to determine if the bedtime blood glucose level by finger stick was associated with the development of nocturnal hypoglycemia and to identify a specific bedtime glucose level at which hypoglycemia was reduced to a prevalence of ≤10%. It was the purpose of this report to describe our findings associating bedtime blood glucose concentrations by finger stick of ≤100 mg/dL and ≤150 mg/dL with nocturnal hypoglycemia, defined as ≤40 mg/dL and ≤50 mg/dL on sensor tracings, in children and teens who used CGMS for up to 3 to 6 days.
METHODS

Patient Population
Pediatric patients with type 1 diabetes were recruited for this study during routine clinic visits to the Comprehensive Diabetes Center at Childrens Hospital Los Angeles during a 6-month period at the end of 1999 and the beginning of 2000. The protocol used, as well as some of the data reported in this study, have been previously described. 12 After being shown the sensor and given an explanation of what a 3-to 6-day sensor wear entailed, 47 of 50 subjects and parents agreed to participate and signed informed consent. The mean age of subjects was 11.8 ± 4.6 years, the youngest child being 2.7 years old. There were 18 boys and 29 girls. Patients had a mean duration of diabetes of 5.5 ± 3.5 years and a mean hemoglobin A1c (HbA1c) of 8.6% ± 1.6%; 24 subjects took 3 to 4 insulin injections per day of rapid-acting and intermediate-acting insulin and 23 subjects used continuous subcutaneous insulin infusion (CSII) with rapid-acting insulin. From these subjects, 167 nights were analyzed because the following criteria were met: (1) there was a bedtime blood glucose by finger stick recorded and (2) there were subsequent sensor values throughout the night.
Study Protocol
Patients and parents were brought to the outpatient clinic at Childrens Hospital Los Angeles for a 2-hour session after informed consent was obtained. At that time, the sensor was placed and patients and parents were trained on how to use CGMS. Sensor placement was done by one of two Certified Diabetes Educators after EMLA Cream (Astra Pharmaceuticals, LP, Wayne, Penn) pretreatment of the abdominal skin. Calibration of the sensor was accomplished by following the protocol established and outlined in the MiniMed CGMS manual.
During CGMS use, patients and parents were instructed to continue to measure a minimum of 4 finger stick blood glucose levels per day and to record blood glucose values, meals and snacks, insulin doses, and symptomatic hypoglycemia in a logbook. They were also instructed how to code these events into the CGMS monitor. If finger stick blood glucose levels were ≤100 mg/dL at bedtime, they were instructed to ingest 50% more carbohydrate than usual at bedtime as 1.5 times their usual snack (typical snacks included cereal and milk, crackers and peanut butter or cheese, bagel, cookies, and so forth, without uncooked cornstarch).
At the completion of the CGMS period, the system was returned and the data were downloaded by the CGMS comstation to determine glucose patterns. Logbooks were also analyzed to determine finger stick blood glucose levels.
Data Analysis
A total of 167 nights of CGMS tracings were analyzed for the occurrence of hypoglycemia defined in two ways: any sensor value ≤40 mg/dL and any sensor value ≤50 mg/dL. Data were evaluated for the entire night, from 9 PM to 9 AM; for distinct periods throughout the night, from 9 PM to 1 AM, 1 to 5 AM, and 5 to 9 AM; and for hourly periods through the night. Patients were instructed to eat breakfast at 8 to 9 AM and to be completed by 9 AM. Separate analyses were done comparing bedtime blood glucose levels by finger stick of >100 mg/dL versus ≤100 mg/dL and >150 mg/dL versus ≤150 mg/dL. The average duration of hypoglycemic events were compared for when the bedtime blood glucose level by finger stick was >100 mg/dL versus ≤100 mg/dL. In addition, data were analyzed to identify a bedtime blood glucose value for which nocturnal hypoglycemia occurred ≤10% of the time and to determine the optimum bedtime blood glucose value that would best predict nocturnal hypoglycemia by sensor. Comparisons were made between the injection therapy versus the CSII therapy groups regarding the occurrence of nocturnal hypoglycemia by sensor (defined as ≤40, ≤50, and ≤60 mg/dL) and the mean night-time blood glucose levels. HbA1c was correlated with the number of sensor values ≤40 and ≤50 mg/dL and the duration of hypoglycemia.
Statistical Analyses
Nocturnal CGMS tracings were categorized into two groups, depending on whether the value of the bedtime blood glucose was less than or equal to a particular threshold, 100 mg/dL or 150 mg/dL, versus whether it was greater than that threshold. The Fisher exact test was used to compare these different groups for the occurrence of nocturnal hypoglycemic events. An independentsample t test was used to determine if the difference in the mean duration of hypoglycemic events was statistically significant throughout the night. A receiver operator curve analysis was con-VOLUME 141, NUMBER 5 ducted to identify a bedtime blood glucose value that reduced the incidence of a nocturnal hypoglycemia event to ≤10%. The Fisher exact test was used to determine if the occurrence of hypoglycemia was significantly different in patients receiving injections versus patients receiving CSII therapy. Multivariate analysis of variance was used to determine if type of therapy had an effect on the overall hourly average glucose, and an independent-sample t test was used to identify significant differences in average glucose at each individual hour. Pearson product-moment correlation was used to assess the relation between frequency of hypoglycemia and HbA1c.
RESULTS
The mean bedtime blood glucose level by finger stick was 185 ± 94 mg/dL, with a median of 165 mg/dL and a range of 41 to 400 mg/dL. There was a sensor value of ≤40 mg/dL on 45 nights (27%) and ≤50 mg/dL on 59 nights (35%). Table I demonstrates the effect of going to bed with a blood glucose level of ≤100 mg/dL compared with >100 mg/dL on the total night-time sensor glucose level and for distinct time periods throughout the entire night. When subjects went to bed with a blood glucose level ≤100 mg/dL compared with a glucose level >100 mg/dL, there was a significant association of having a sensor glucose level of ≤40 mg/dL during the entire night. A similar association was seen during the 9 PM to 1 AM time period. There was also a significant association of having a sensor glucose level of ≤50 mg/dL when going to bed with a blood glucose level ≤100 mg/dL during the entire night and during the 9 PM to 1 AM time period. Table II gives the results comparing bedtime blood glucose levels by finger stick of ≤150 mg/dL and >150 mg/dL. Going to bed with a blood glucose level of ≤150 mg/dL was associated with the development of a sensor glucose level of ≤50 mg/dL during the night as a whole and during the specific time period of 9 PM to 1 AM. The development of a sensor glucose level of ≤40 mg/dL was not shown to be associated with a bedtime blood glucose level of ≤150 mg/dL.
The average duration of hypoglycemic episodes was also analyzed. The results of the mean duration of hypoglycemia for a bedtime blood glucose value by finger stick of ≤100 mg/dL versus >100 mg/dL are given in Table III . There was no significant difference in the average duration of hypoglycemia for nights with a bedtime blood glucose ≤100 mg/dL versus >100 mg/dL. It is possible that this occurred because patients were told to eat 50% more carbohydrate if they had a bedtime blood glucose value ≤100 mg/dL.
Analyses of blood glucose values from 110 mg/dL to 300 mg/dL (by increments of 10) were not able to demonstrate a blood glucose value that reduced the incidence of nocturnal hypoglycemia to <10%. A receiver operator curve analysis was conducted to determine the bedtime blood glucose value that best predicted whether a patient would have a nocturnal event. It was found that there was no bedtime blood glucose value that would best predict nocturnal hypoglycemia. This analysis may also have been affected by increasing carbohydrate intake if the bedtime blood glucose was ≤100 mg/dL.
Overall occurrence and hourly comparisons from 9 PM to 9 AM of CSII therapy versus injection therapy yielded no difference when evaluating for nocturnal hypoglycemia by using bedtime blood glucose levels ≤40, ≤50, and ≤60 mg/dL. Sixty-five percent of patients using the pump and 50% of patients taking insulin injections had a sensor glucose value during the night of ≤40 mg/dL; 75% of patients using the pump and 59% of patients taking injections had a sensor value ≤50 mg/dL; and 79% of patients using the pump and 73% of those taking injections had a value ≤60 mg/dL (P > .05). However, there was a trend toward lower mean sensor glucose levels in the pump group throughout the night (pump, 173 ± 60 mg/dL vs injection, 195 ± 52 mg/dL, P = .21) and specifically at 6 AM to 7 AM (pump, 158 ± 70 mg/dL versus injections, 199 + 75 mg/dL, P = .07) and 8 AM to 9 AM (pump, 175 ± 67 mg/dL versus injections, 213 ± 68 mg/dL, P = .07). The lack of statistical significance may have been due to the relatively small sample size and large variability in the average sensor glucose levels. Table I . Association of the number of nights with bedtime blood glucose of ≤100 mg/dL or >100 mg/dL and nighttime glucose levels of ≤40 mg/dL and ≤50 mg/dL There was no correlation between HbA1c and the number of sensor readings ≤50 mg/dL (r = -0.14, P = .46) or the duration of hypoglycemia ≤50 mg/dL (r = 0.24, P = .22). Similarly, there was no correlation between HbA1c and the number of sensor readings ≤40 mg/dL (r = -0.15, P = .49) or the duration of hypoglycemia at that sensor level (r = 0.29, P = .17).
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DISCUSSION
The use of CGMS in this study substantiated what has been documented in previous studies-that nocturnal hypoglycemia is a common occurrence in children and youth with type 1 diabetes [6] [7] [8] [9] [10] and that these hypoglycemic episodes are of relatively long duration. 10, 13 Regardless of the bedtime blood glucose level, there was a 27% chance of an episode of nocturnal hypoglycemia when defined as a sensor glucose value ≤40 mg/dL and a 35% chance when defined as a sensor glucose value ≤50 mg/dL. The prevalence rates of nocturnal hypoglycemia in our study for sensor glucose levels ≤40 mg/dL and ≤50 mg/dL are supportive of the higher prevalence rate of 47% found by Beregszaszi et al. 7 They most likely found a higher prevalence rate because a higher plasma glucose cutoff of ≤60 mg/dL was used to define hypoglycemia.
The main purpose of this study was to determine the bedtime glucose level at which nocturnal hypoglycemia was reduced to ≤10% prevalence. Our data showed that there was no bedtime blood glucose level between 110 and 300 mg/dL that was associated with a reduction in nocturnal hypoglycemia to ≤10%. However, there was an association between a bedtime blood glucose level ≤100 mg/dL and the occurrence of a sensor glucose level ≤40 mg/dL at some point during the night and an association between a bedtime blood glucose value of ≤150 mg/dL and a sensor glucose value of ≤50 mg/dL during the night. As a result, there was a 2-fold increase in risk of hypoglycemia when the bedtime glucose value was ≤100 mg/dL and a 1.7-fold increase in risk with a value ≤150 mg/dL. Since our subjects ingested 50% more than the usual bedtime snack if their bedtime finger stick blood glucose was ≤100 mg/dL, it is likely that the occurrence of nocturnal hypoglycemia may have been even greater if the added snack had not been taken. In addition, the predominance of hypoglycemic episodes occurred between 9 PM and 1 AM. This early nighttime occurrence of the greatest number of hypoglycemic episodes was similar to that reported by Beregszaszi et al, 7 who found that two thirds of the initial episodes of hypoglycemia occurred between 10 PM and midnight.
Our study substantiated the utility of bedtime blood glucose monitoring 1 to determine the risk of the development of nocturnal hypoglycemia. It would appear that if the bedtime value is ≤100 mg/dL, glucose testing between 9 PM and 1 AM is indicated to detect early night-time hypoglycemia. This might not be difficult to do because most parents go to bed during that time period. Glucose testing probably could be performed without interrupting the child's sleep, and, when indicated, treatment with additional simple and complex carbohydrates might help ameliorate hypoglycemia. Our study would also suggest that all children are at risk, regardless of HbA1c or treatment regimen. On the other hand, our study did not specifically evaluate the effectiveness of altering the bedtime snack to avert hypoglycemia if the bedtime glucose level was ≤100 mg/dL. However, since Porter et al 8 beneficial effect of altering the bedtime snack as a preventive for hypoglycemia, further studies with CGMS are indicated to determine if increasing the carbohydrate portion of the regular bedtime snack or adding agents such as uncooked cornstarch, which was not used by our patients during this study, might help reduce nocturnal hypoglycemic episodes.
Although it might have been anticipated that the occurrence of hypoglycemia during the night, especially from 9 PM to 1 AM, was associated with the use of intermediate-acting insulin at bedtime, our results did not show a higher rate of hypoglycemia in those on injection therapy versus CSII. Rather, our results substantiated those of Tsui et al, 14 who showed no significant difference in glycemic control or hypoglycemic events in adult subjects randomly assigned to CSII or injection therapy with night-time neutral protamine Hagedorn insulin. Although we showed a trend toward lower morning glucose levels with CSII, there was no statistical difference compared with the morning glucose levels of our subjects on insulin injections. The occurrence of nocturnal hypoglycemia was not the result of using short-acting (regular) insulin, with its longer duration of action and delayed onset of action compared with rapid-acting insulin analogues, because the patients in our study did not use regular insulin. The use of rapidacting insulin in CSII and as the dinner bolus insulin for those taking insulin injections became our standard practice after rapid-acting insulin was reported to decrease overall hypoglycemia rates. 15, 16 Many factors, such as young age, 7, 9, 17, 18 longer duration of diabetes, 18 and insulin dosage >0.85 U/kg per day, 7 have been described to increase the risk of nocturnal hypoglycemia. In addition, extremely low and labile blood glucose values over the preceding 2 to 3 weeks have been found to be good predictors of subsequent nocturnal hypoglycemic events. 6 The Diabetes Control and Complications Trial findings of an increased risk of hypoglycemia with intensive treatment and lower HbA1c 3 was not substantiated by our study, which showed no correlation with HbA1c and the incidence or duration of nighttime hypoglycemia.
The current study substantiates the fact that nocturnal hypoglycemia is frequent, of long duration, associated with bedtime blood glucose values ≤100 to 150 mg/dL, and predominately in the early part of the night. It has been determined by Chase et al 19 and corroborated by this study that CGMS is a useful tool in determining the occurrence of asymptomatic nocturnal hypoglycemia and that continued use of CGMS might better help determine risk profiles for hypoglycemia. This information should be used to help reduce episodes of nocturnal hypoglycemia while we await the development of continuous glucose sensors that can provide real-time glucose values that will offer the potential to substantially reduce nocturnal hypoglycemia.
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It was in 1933 that the American Board of Pediatrics (ABP) came into existence in response to the need to establish standards for the training and evaluation of pediatricians. The American Academy of Pediatrics, the American Pediatric Society, and the Pediatric Section of the American Medical Association were instrumental in the formation of the ABP and also in establishing it as an independent entity, one designed to be free of professional conflicts of interest, whose mission it was to assure the public of the competence of pediatricians who voluntarily certify. Seventy years later, the ABP remains an independent organization whose sole purpose relates to the public interest.
By the fall of 1952, when this journal reviewed the first 20 years of the ABP's experience, there were relatively few pediatricians, in fact, just 4076. There were no subspecialty certificate holders. The first subspecialty certification examination came in 1961 when 54 pediatric cardiologists were examined and certified as subspecialists. Other subspecialty examinations followed. There are now 16 subspecialty certificates awarded by the ABP (cardiology, hematology-oncology, nephrology, neonatal-perinatal medicine, endocrinology, pulmonology, critical care medicine, gastroenterology, emergency medicine, rheumatology, sports medicine, adolescent medicine, infectious diseases, medical toxicology, neurodevelopmental disabilities, and developmental-behavioral pediatrics). As 2002 began, 74,592 general pediatric certificates have been issued, along with 13,791 subspecialty certificates.
Much else has changed in the last 50 years. Each year, the ABP certifies more than 4 times the total number of candidates in general pediatrics than in 1952. There are now more women certified than men. In 1952, all certificates were awarded without time limit. There was no recertification. The public had to assume that a pediatrician once certified remained competent. This changed in 1988 when the first time-limited certificates were given. Now, all generalists and subspecialists are expected to voluntarily recertify every 7 years.
Challenges remain for the certification processes used by all boards. It is no longer considered adequate to assure the public that a certified physician merely knows the required content of a discipline. The expected competencies of certificate holders now include professionalism, the ability to communicate effectively, to practice appropriately within the multiple systems of healthcare that now exist, and to provide quality care that is sensitive to the specific needs of individual patients. These expanded competencies have been incorporated into the Maintenance of Certification programs of all boards. It will be interesting to see what the next 50 years hold for the certification process as new technologies are developed and patient and family needs change. If there are as many changes coming in the next half century as there have been since 1952, the commentary that appears in this journal in 2052 should make for some interesting reading.
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